[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"China Medical University, China\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":524},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,22,0,[8,48,70,97,119,140,163,181,208,235,261,280,301,314,342,363,389,413,435,455,481,502],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100645080",false,"NCT07679828","Polypills Approach for Multiple Cardiovascular Risk Factors","Polypills Approach for Multiple Cardiovascular Risk Factors (PACIF) : a Multicentre, Open-label, Randomized Controlled Trial","PACIF","Inclusion Criteria:\n\n* Men or women\n* Age ≥50 years and \\\u003C75 years\n* Hypertension, defined as systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg among participants not currently taking antihypertensive medication, or systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥80 mmHg among participants currently taking any antihypertensive medication\n* Dyslipidemia, defined as LDL-C ≥1.8 mmol\u002FL (70 mg\u002FdL)\n* Type 2 diabetes with HbA1c ≥6.5% and \\\u003C12%\n* Willing to participate and able to sign informed consent\n\nExclusion Criteria:\n\n* Known secondary cause of hypertension\n* Type 1 diabetes\n* Pancreatic insufficiency or diabetes secondary to pancreatitis\n* Triglycerides ≥5.65 mmol\u002FL (500 mg\u002FdL)\n* History of coronary, carotid, or cerebrovascular revascularization within the previous 12 months\n* History of myocardial infarction or stroke within the previous 6 months\n* NYHA class III-IV heart failure at entry or hospitalization for exacerbation of chronic heart failure within the previous 6 months\n* Abnormal kidney function, defined as estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m² or dialysis\n* Abnormal liver function, defined as alanine aminotransferase or aspartate aminotransferase \\>3 times the upper limit of normal\n* Abnormal serum potassium, defined as serum potassium \\>5.5 mmol\u002FL or \\\u003C3.5 mmol\u002FL\n* Contraindication to any of the components of the polypill\n* Currently living with another PACIF participant\n* Pregnancy, currently trying to become pregnant, or of child-bearing potential and not using birth control\n* Clinical diagnosis of dementia or treatment with medications for dementia\n* History of malignancy\n* Life expectancy \\\u003C3 years\n* Currently participating in another intervention study\n* Any factors judged by the clinic team to be likely to limit adherence to interventions","ALL","50 Years","75 Years",{"count":20,"type":21},8252,"ESTIMATED","INTERVENTIONAL",[24],"NA","The Polypill Approach for Multiple Cardiovascular Risk Factors (PACIF) trial is a multicenter randomized controlled trial that will test the effectiveness and safety of a fixed-dose combination strategy for integrated management of hypertension, dyslipidemia, and diabetes among adults aged 50 to 75 years in China. The trial will evaluate whether a simplified regimen combining blood pressure-lowering, lipid-lowering, and glucose-lowering therapy improves the 10-year cardiovascular disease risk score at phase 1. Participants will be followed to determine whether the fixed-dose combination strategy reduces major cardiovascular events and cognitive function compared with usual care at phase 2.",[27,28,29],"Hypertension","Dyslipidemia","Diabetes",[27,28,29,31,32,33,34,35],"Polypill","Cardiovascular disease risk","Cardiovascular Diseases","Cognitive function","Randomized controlled trial","NOT_YET_RECRUITING","2026-06-25",{"date":39,"type":40},"2026-07-01","ACTUAL",{"date":39,"type":21},{"date":43,"type":21},"2030-03-01",{"name":45,"class":46},"China Medical University, China","OTHER",12,{"id":49,"slug":4,"hasResults":10,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":10,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":4},"100638704","NCT07629531","Applied Research on a Non-pharmacological Intervention Program for Older Adults With Subjective Cognitive Decline","Applied Research on a Group-based Non-pharmacological Intervention Program for Community-dwelling Older Adults With Subjective Cognitive Decline","Inclusion Criteria Aged ≥60 Community dwelling Subjective memory decline, confirmed by Subjective Cognitive Decline Questionnaire(SCD-Q9)≥5 Montreal Cognitive Assessment (MoCA) scores ≥19, 22, or 24 for participants who had primary school, middle school, or higher education, respectively Overall intact activities of daily living No planned exercise or cognitive intervention activities within the past six months Voluntary participants who will be informed of the study objectives by the researcher and will sign the informed consent form.\n\nExclusion Criteria Any other neurodegenerative diseases (such as mild cognitive impairment, dementia, Parkinson's disease, stroke, etc.) Any severe or unstable internal medical conditions (i.e., unstable or severe asthma or heart disease, liver and kidney diseases, uncontrolled hypertension, severe metabolic diseases, etc.) Severe depressive, anxiety or other psychiatric disorders Movement contraindications Those currently participating in other research trials.","60 Years","85 Years",{"count":57,"type":21},218,[24],"This study aims to verify the short-term and long-term effects of a group-based non-pharmacological intervention program for community-dwelling older adults with subjective cognitive decline, and to evaluate its implementation outcomes, through a rigorously designed cluster randomized controlled trial.",[61],"Non-Pharmacological Interventions","2026-06-01",{"date":64,"type":40},"2026-06-05",{"date":66,"type":21},"2026-06-30",{"date":68,"type":21},"2029-12-01",{"name":45,"class":46},{"id":71,"slug":4,"hasResults":10,"nctId":72,"briefTitle":73,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":22,"phases":79,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":96},"100632911","NCT07519837","Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics","PRCC-MO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Signed informed consent form and voluntary participation in this study\n* Histologically and\u002For cytologically confirmed diagnosis of cancer\n* Patients with gastrointestinal malignancies, including:\n* Esophageal cancer\n* Hepatocellular carcinoma\n* Gastric cancer\n* Cholangiocarcinoma\n* Patients undergoing histopathological examination of primary lesion biopsy or gastrointestinal endoscopic biopsy\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Presence of contraindications to surgery\n* Cognitive dysfunction, psychiatric disorders, impaired consciousness, or inability\u002Funwillingness to cooperate\n* Presence of two or more concurrent primary tumors","18 Years",{"count":78,"type":21},1000,[24],"Cancer cachexia is a complex systemic metabolic syndrome with high incidence and mortality rates, significantly impacting the prognosis and survival of cancer patients.Current clinical comprehensive intervention approaches can only provide transient symptom relief and fail to fundamentally block or reverse muscle and fat loss. The core challenge lies in the extreme complexity of this pathological mechanism and the lack of early biomarkers.To overcome the limitations of traditional single-dimensional research approaches, this study proposes a combined analysis method utilizing \"multi-omics\" (imaging omics, pathological omics, metabolomics, and metagenomics) to construct a panoramic systemic model spanning macroscopic clinical manifestations and microscopic molecular processes. The aim is to comprehensively elucidate the pathogenesis and metabolic pathways of cachexia, thereby precisely identifying potential therapeutic targets capable of reversing this pathological process.",[82],"Cachexia; Cancer; Sarcopenia",[84,85,86],"cancer associated cachexia","Multi-omics Integrated Analysis","Mechanism Exploration and Reversal Strategy Research","RECRUITING","2026-04-02",{"date":90,"type":40},"2026-04-09",{"date":92,"type":40},"2026-03-18",{"date":94,"type":21},"2028-03-20",{"name":45,"class":46},1,{"id":98,"slug":4,"hasResults":10,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":108,"conditions":109,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":4},"100622842","NCT07388875","Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC","A Single-arm, Phase II Study of Sacituzumab Tirumotecan Combined With Anlotinib in Patients With Extensive-stage Small Cell Lung Cancer After Failure of PD-(L)1 Inhibitor Plus Chemotherapy","SKB264-ANLO","Inclusion Criteria:\n\n* Age ≥18 years at the time of signing informed consent; male or female.\n* Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).\n* Disease progression after receiving only one prior line of therapy consisting of a PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy.\n* At least one measurable target lesion per RECIST v1.1 as assessed by the investigator, which has not been previously irradiated.\n* Patients with asymptomatic brain metastases, or patients with treated brain metastases and stable symptoms for ≥4 weeks, are eligible.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Estimated life expectancy of at least 12 weeks.\n* Adequate organ and bone marrow function (no blood transfusion, recombinant human thrombopoietin, or colony-stimulating factors within 2 weeks prior to first dose), defined as follows:\n* Hematologic function:\n* Absolute neutrophil count ≥1.5 × 10⁹\u002FL\n* Platelet count ≥100 × 10⁹\u002FL\n* Hemoglobin ≥90 g\u002FL\n* Hepatic function:\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 × ULN; for patients with liver metastases, AST and ALT ≤5 × ULN\n* Albumin ≥30 g\u002FL\n* Total bilirubin ≤1.5 × ULN\n* Renal function:\n* Creatinine clearance ≥50 mL\u002Fmin, calculated using the Cockcroft-Gault formula\n* Coagulation function:\n* International normalized ratio (INR), activated partial thromboplastin time (APTT), and prothrombin time (PT) ≤1.5 × ULN\n* Women of childbearing potential and men with partners of childbearing potential must agree to use effective medical contraception from signing informed consent until 6 months after the last dose of study treatment.\n* Subjects must voluntarily participate in the study, provide written informed consent, and be able to comply with protocol-required visits and study procedures.\n\nExclusion Criteria:\n\n* Participation in another interventional drug clinical trial within 4 weeks prior to enrollment.\n* Tumors with a high risk of massive hemoptysis, as judged by the investigator.\n* Prior systemic anti-tumor therapy with anti-angiogenic agents.\n* Prior treatment with TROP2-targeted therapies and\u002For topoisomerase I inhibitors.\n* History of other malignancies within the past 5 years, except for adequately treated cervical carcinoma in situ, basal cell carcinoma of the skin, or squamous cell carcinoma of the skin.\n* Known hypersensitivity or allergy to any investigational product or its components.\n* Known positive human immunodeficiency virus (HIV) infection, history of acquired immunodeficiency syndrome (AIDS), or known active syphilis infection.\n* History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.\n* Receipt of live vaccines within 30 days prior to the first dose of study treatment.\n* History of interstitial lung disease (ILD) or non-infectious pneumonitis requiring steroid treatment; current ILD or non-infectious pneumonitis; or suspected ILD or non-infectious pneumonitis that cannot be excluded by imaging at screening. Severe pulmonary impairment due to pulmonary comorbidities, including but not limited to:\n* Pulmonary embolism within 3 months prior to first dose\n* Severe asthma\n* Severe chronic obstructive pulmonary disease\n* Restrictive lung disease\n* Pleural effusion\n* Autoimmune, connective tissue, or inflammatory diseases involving the lungs (e.g., rheumatoid arthritis, Sjögren's syndrome, sarcoidosis)\n* Prior pneumonectomy\n* Active autoimmune disease requiring systemic treatment within the past 2 years (hormone replacement therapy is not considered systemic treatment, such as type 1 diabetes mellitus, hypothyroidism requiring only thyroid hormone replacement, or adrenal or pituitary insufficiency requiring physiologic doses of corticosteroids).\n* Active infection requiring systemic therapy within 2 weeks prior to the first dose of study treatment.\n* Serious concomitant diseases that, in the investigator's judgment, may compromise patient safety or interfere with completion of the study, including but not limited to uncontrolled hypertension, severe diabetes mellitus, or active infection.\n* Documented severe dry eye syndrome, severe meibomian gland dysfunction and\u002For blepharitis, or a history of corneal disorders that may interfere with delayed corneal healing.\n* Pregnant or breastfeeding women; women of childbearing potential with a positive baseline pregnancy test; or women of childbearing potential who are unwilling to use effective contraception during study treatment and for 6 months after the last dose of study treatment.\n* Any other condition that, in the investigator's opinion, makes the patient unsuitable for participation in the study.",{"count":105,"type":21},30,[107],"PHASE2","This is a Phase II, single-arm, open-label clinical study to evaluate the efficacy and safety of Sacituzumab Tirumotecan (SKB264) combined with Anlotinib in patients with extensive-stage small cell lung cancer (ES-SCLC). The study is designed for patients who have experienced disease progression or treatment failure after prior first-line therapy with a PD-(L)1 inhibitor combined with platinum-based doublet chemotherapy. The primary hypothesis is that this combination therapy will improve the objective response rate compared to historical controls.",[110],"Extensive-Stage Small Cell Lung Cancer","2026-01-28",{"date":113,"type":40},"2026-02-05",{"date":115,"type":21},"2026-02-24",{"date":117,"type":21},"2027-08-01",{"name":45,"class":46},{"id":120,"slug":4,"hasResults":10,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":10,"sex":16,"minAge":124,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":22,"phases":127,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":138,"locationsCount":139},"100543687","NCT06359106","Effects of Different Inhaled Oxygen Concentrations on Lung Function in Older Patients After Laparoscopic Gastrointestinal Surgery Under General Anesthesia","Inclusion Criteria:\n\n* Age not less than 65 years\n* American Society of Anesthesiologists grades I-III\n* No history of drug allergies or abnormal anesthesia.\n* The duration of mechanical ventilation was expected to be more than 2 hours.\n* Laparoscopic Gastrointestinal Surgery\n* The preoperative oxygen saturation was not less than 94%.\n* The patients will be planned to extubate in the operating room.\n\nExclusion Criteria:\n\n* History of acute lung injury or acute respiratory distress syndrome (ARDS) within 3 months.\n* Cardiac function Class IV (New York Heart Association classification)\n* Chronic renal failure (renal cell filtration rate \\\u003C30 ml min-11.73\u002Fm2), severe liver disease\n* Patients with blurred consciousness and cognitive dysfunction\n* Severe coagulation dysfunction.\n* Without preoperative oxygen inhalation, blood oxygen level \\\u003C94%, and severe pulmonary dysfunction\n* Patients with endotracheal tubes were admitted to the intensive care unit (ICU) after surgery.\n* Body mass index (BMI) \\>30kg\u002Fm2\n* Inability to complete the study","65 Years",{"count":126,"type":21},1176,[128],"PHASE4","This was a multicenter, prospective, parallel-grouping, randomized controlled clinical study comparing low FiO2 (40%) and high FiO2 (80%) levels in older patients undergoing laparoscopic gastrointestinal surgery.",[131],"Oxygenation Index","2026-01-23",{"date":134,"type":40},"2026-01-26",{"date":136,"type":40},"2024-07-02",{"date":66,"type":21},{"name":45,"class":46},16,{"id":141,"slug":4,"hasResults":10,"nctId":142,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":144,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":151,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":4},"100621890","NCT07376499","Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction","Inclusion Criteria:\n\n* 1\\. Volunteer to join the study, sign the informed consent and sign the date, have good compliance, and cooperate with follow-up 2. Age≥18 years 3. Diagnosis of extensive stage small cell lung cancer (ES-SCLC) confirmed histologically or pathologically (according to American Veterans Lung Cancer Association, VALG staging) 4. ECOG 0-2 5. Subjects had not received any systemic treatment for ES-SCLC in the past (including chemotherapy, use of similar VEGFR inhibitors and immune checkpoint inhibitors, etc.) 6. Subjects with limited-stage small cell lung cancer (LS-SCLC) have received radiotherapy, chemotherapy, or chemoradiotherapy for more than 6 months 7. Expected survival ≥ 3 months 8. Must have measurable target lesions that meet RECIST1.1 criteria (CT scan length of tumor lesion \\>10mm); In patients with initial asymptomatic brain metastases, craniocerebral radiotherapy may be performed during induction chemotherapy 9. If the major organs are functioning normally, the following criteria are met:\n\n  1. Blood routine examination must meet (no blood transfusion within 14 days, no hematopoietic factor and no drug correction) : ANC ≥ 1.5×10\\^9\u002FL; HB ≥ 90 g\u002FL; PLT ≥ 100×10\\^9\u002FL\n  2. Biochemical examination must meet the following criteria: TBIL ≤ 1.5ULN; ALT and AST≤ 2.5ULN;\n  3. Renal function must meet the following criteria: serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥40 mL\u002Fmin (using the standard Cockcroft-Gault formula)\n  4. Coagulation function must meet: INR≤1.5 and APTT≤1.5ULN 10. Female who are fertile must have a serum or urine pregnancy test within 72 hours before the first medication and the result is negative. Fertile female and male subjects whose partners are fertile female must agree to a highly effective method of avoiding and breastfeeding during the study period until 90 days after the last dose of the study drug. The investigator or designee, in consultation with the subject, shall confirm that the subject understands the proper and consistent use of contraceptive methods 11. For males, they should be surgically sterilized or consent to a highly effective method of avoidance during the trial and for 90 days after the last administration of the experimental drug 12. Female participants had to agree not to breastfeed during the study period or for 180 days after the last dose of study treatment\n\nExclusion Criteria:\n\n* 1\\. Patients with meningeal metastases or symptomatic brain metastases 2. Previous T cell co-stimulation or immune checkpoint therapy, including but not limited to cytotoxic T lymphocyte-associated antigen-4 (CTLA-4)inhibitors, PD-1 inhibitors, PD-L1\u002F2 inhibitors, CD137 agonists, or other targeting T cell drugs; 3. Past treatment with anlotinib 4. Factors affecting oral medication, such as inability to swallow, post-GI resection, chronic diarrhea, intestinal obstruction, etc 5. Uncontrollable pleural effusion or ascites 6. Have any active autoimmune disease or history of autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (may be included after hormone replacement therapy), tuberculosis); Patients with skin conditions (such as vitiligo, psoriasis, or alopecia) that have been in complete remission from childhood asthma and do not require any intervention in adulthood and do not require systemic treatment may be included. Patients who require medical intervention with bronchodilators may not be included 7. Patients with congenital or acquired immunodeficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500IU\u002Fml), hepatitis C (HCV antibody positive and HCV-RNA above the lower detection limit of analytical methods), or co-infection with hepatitis B and hepatitis C 8. Urine routine suggests urinary protein ≥(++), or 24h urinary protein ≥2g or severe hepatic and renal insufficiency 9. Patients requiring systemic therapy with corticosteroids (\\>10mg\u002F day of prednisone or equivalent) or other immunosuppressants within 14 days prior to initial medication. In the absence of active autoimmune disease, inhaled or topical corticosteroids are permitted, as well as adrenal hormone replacement therapy at doses \\>10 mg\u002F day of prednisone efficacy 10. Patients who have been treated with anti-tumor vaccine or other immunostimulating anti-tumor agents (interferon, interleukin, thymosin, immunocell therapy, etc.) within 1 month prior to initial medication 11. Other malignant neoplasms were present within 5 years prior to admission, except for adequately treatable carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery 12. There is evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiological pneumonia, drug-induced pneumonia, radiologically proven active pneumonia, and severe impairment of lung function 13. Uncontrolled hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90mmHg, despite optimal medical treatment 14. Patients with grade II or higher myocardial ischemia or myocardial infarction and poorly controlled arrhythmias (including QTc interval\n\n  * 450ms in men and ≥470ms in women). According to the NYHA criteria, patients with grade III to # cardiac insufficiency, or those with left ventricular ejection fraction (LVEF) \\\u003C 50% indicated by color Doppler ultrasound had myocardial infarction in the 6 months prior to enrollment, heart failure of New York Heart Society grade II or above, uncontrolled angina, uncontrolled severe ventricular arrhythmia, clinically significant pericardial disease, and myocardial infarction. Or electrocardiogram suggests acute ischemia or abnormal active conduction system 15. Concurrent severe infection within 4 weeks prior to first dosing, or unexplained fever \\>38.5°C during screening\u002Fprior to first dosing 16. Major surgery, open biopsy, or significant trauma were performed within 28 days prior to enrollment 17. Aortic\u002Fvenous thrombosis occurred within 6 months 18. The researchers assessed possible risk of severe hemoptysis, bleeding events, or wearing 19.Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation 20.Pregnant or lactating women; Fertile patients who are unwilling or unable to use effective contraception 21.Allergic reaction to any investigational drug or its ingredients 22.Any condition that the investigator believes is likely to harm the subject or cause the subject to be unable to meet or perform the study requirements",{"count":146,"type":21},31,[107],"To evaluate the efficacy and safety of liposome irinotecan combined with platinum and immune checkpoint inhibitor combined with antirotinib maintenance therapy after first-line induction",[150],"Small Cell Lung Cancer",[150,152,153,154],"liposome irinotecan","platinum","immune checkpoint inhibitor","2026-01-22",{"date":157,"type":40},"2026-01-29",{"date":159,"type":21},"2026-01-25",{"date":161,"type":21},"2027-06-30",{"name":45,"class":46},{"id":164,"slug":4,"hasResults":10,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":18,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":96},"100621695","NCT07373964","A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)","A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Tablets Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)","Inclusion Criteria:\n\n* Age ≥18 and ≤75 years.\n* Histologically confirmed ES-SCLC, unsuitable for local radical therapy.\n* No prior systemic therapy for ES-SCLC.\n* ECOG performance status 0-1.\n* At least one measurable lesion per RECIST v1.1.\n* Expected survival ≥3 months.\n* Adequate organ function (hematological, hepatic, renal, cardiac).\n* Effective contraception from consent until 180 days after last dose.\n* For active HBV infection: HBV DNA \\\u003C2000 IU\u002FmL within 28 days before treatment and on stable antiviral therapy.\n* Recovery from prior therapy toxicities to ≤ Grade 1 (except alopecia).\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Factors significantly affecting oral drug absorption.\n* Prior HDAC inhibitor or immune checkpoint inhibitor therapy.\n* Known allergy to any study drug component.\n* Other malignancy within past 5 years (except certain cured cancers).\n* Participation in another clinical trial within 4 weeks.\n* Immunodeficiency, HIV positivity, or organ transplant history.\n* Uncontrolled cardiovascular disease or QTc \\>450 ms.\n* Pregnancy, lactation, or unwillingness to use effective contraception.\n* Other severe comorbid conditions deemed unsafe by investigator.\n* History of neurological or psychiatric disorders.\n* Any condition making the patient unsuitable per investigator judgment.",{"count":170,"type":21},36,[107],"This is a Phase II, single-arm, single-center study evaluating Chidamide combined with a PD-L1 inhibitor, carboplatin, and etoposide as first-line therapy in extensive-stage small-cell lung cancer (ES-SCLC) patients. The primary objective is to assess Progression-Free Survival (PFS) per RECIST v1.1. Secondary objectives include Objective Response Rate (ORR), Disease Control Rate (DCR), Duration of Response (DOR), Overall Survival (OS), and safety. Approximately 36 participants will receive induction therapy (Chidamide + chemotherapy + PD-L1 inhibitor) for 4 cycles, followed by Chidamide maintenance until progression or unacceptable toxicity.",[150],"2026-01-21",{"date":111,"type":40},{"date":177,"type":40},"2025-10-15",{"date":179,"type":21},"2027-10-14",{"name":45,"class":46},{"id":182,"slug":4,"hasResults":10,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":4},"100537846","NCT06283134","A Clinical Study of BioTTT001 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer","A Clinical Study to Evaluate the Safety and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Combination With Toripalimab and Regorafenib in Patients With Liver Metastases From Colorectal Cancer","Inclusion Criteria:\n\n1. Age range from 18 to 70 years old (including the threshold), no gender restrictions;\n2. Patients with a definitive histopathological or cytological diagnosis of colorectal cancer with hepatic metastases who have received and failed at least second-line standard therapy in the past, or who have been assessed by the investigator to be unsuitable for standard therapy;\n3. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1;\n4. WBC≥3.0×10\\^9\u002FL; ANC≥1.5×10\\^9\u002FL (without cytokine therapy within one week before the screening ); Hb≥90g\u002FL(without blood transfusion within one week before the screening);PLT≥90×10\\^9\u002FL(without Platelet transfusion or thrombopoietin (TPO) within one week before the screening)；ALT and AST≤5×ULN；Cr≤1.5×ULN or CCr\\>50mL\u002Fmin; TBIL≤1.5×ULN; APTT≤1.5×ULN and INR\u002FPT≤1.5×ULN；\n5. ECOG 0\\~2；\n6. Expected survival ≥ 3 months;\n7. Consent to contraception；\n8. Understand and voluntarily sign a written ICF and be willing to comply with all trial requirements.\n\nExclusion Criteria:\n\n1. Known allergy to the investigational drug or its components;\n2. Previous treatment with other adenovirus drugs;\n3. Patients with active autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, etc.), except type 1 diabetes, hypothyroidism that only needs hormone replacement therapy, and skin diseases that do not need systemic treatment (such as vitiligo, psoriasis or alopecia);\n4. Received treatment with nitrosourea or mitomycin C within 6 weeks before the first dose of BioTTT001; received oral fluorouracil and small molecule targeted drug therapy within 2 weeks or 5 half-lives of the drug within 2 weeks before the first dose of BioTTT001; received traditional Chinese medicine therapy with anti-tumor indications within 2 weeks before the first dose of BioTTT001; received chemotherapy, radiotherapy, biological therapy other than the drugs mentioned above within 28 days before the first dose of BioTTT001；\n5. Patients who have not recovered from the adverse reactions of previous treatments (the treatment-related toxicity ≤ grade 2, except for alopecia, pigmentation or other tolerable events judged by the investigator ).\n6. History of other malignancies (except cured basal cell skin cancer, cervical carcinoma in situ, Papillary carcinoma of thyroid gland, low-risk GIST etc.) within 5 years before study drug administration;\n7. Patients who have undergone any major surgery (except needle biopsy, etc.) or severe trauma within 4 weeks before the first dose of BioTTT001;\n8. Patients who have been treated with high-dose systemic corticosteroids (prednisone \\> 10 mg\u002Fday or equivalent doses) or other immunosuppressants within 2 weeks before the first dose of BioTTT001;\n9. NYHA≥grade 3; LVEF\\\u003C50%; male QTc\\>450 mms, female QTc\\>470 mms;\n10. Patients with active tuberculosis or drug-induced interstitial lung disease；\n11. Patients with active infection requiring systemic anti-infective therapy;\n12. In a state of immunosuppression, such as severe combined immunodeficiency disease or concurrent opportunistic infections;\n13. HBsAg positive, and blood HBV DNA≥100 IU\u002FmL; anti-HCV positive; HIV positive; active syphilis;\n14. Patients with pleural effusion and ascites with clinical symptoms that require repeated drainage;\n15. Patients with central nervous system metastases or meningeal metastases with clinical symptoms;\n16. Patients with contraindications to hepatic arterial perfusion therapy;\n17. Pregnant or lactating women;\n18. Patients with prior organ transplants;\n19. Other reasons judged by the investigator.","70 Years",{"count":189,"type":21},60,[191],"PHASE1","This is a phase I, open-label clinical study of BioTTT001 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer.",[194],"Colorectal Cancer Metastatic",[196,197,198,199],"oncolytic virus","colorectal Cancer","liver metastasis","hepatic artery infusion","2026-01-04",{"date":202,"type":40},"2026-01-07",{"date":204,"type":21},"2026-03",{"date":206,"type":21},"2028-12-01",{"name":45,"class":46},{"id":209,"slug":4,"hasResults":10,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":214,"sex":16,"minAge":215,"maxAge":216,"enrollmentInfo":217,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":225,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":96},"100613150","NCT07262840","Health Behavior Change in High-Risk Colorectal Cancer Individuals","Facilitating Health Behavior Change in High-Risk Individuals for Colorectal Cancer: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Meets the criteria for being at high-risk for colorectal cancer as defined by the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Colorectal Cancer Screening and the relevant Chinese expert consensus on colorectal cancer diagnosis and treatment.\n* Age ≥ 18 years.\n* Has normal verbal communication and comprehension abilities.\n* Provides informed consent and voluntarily agrees to participate in the study.\n\nExclusion Criteria:\n\n* Has a prior diagnosis of any malignancy (cancer).\n* Has a diagnosed severe psychiatric or psychological disorder.",true,"18 Months","80 Months",{"count":218,"type":21},80,[24],"Background Colorectal cancer is a significant health concern. For individuals identified as being at high risk for developing this disease, adopting healthy lifestyle behaviors is a powerful way to lower that risk. However, starting and maintaining these new habits can be challenging. This study aims to test a comprehensive support program designed to help high-risk individuals make and sustain these positive health behavior changes.\n\nPurpose The main goal of this research is to see if a specially designed 12-week health promotion program can effectively help high-risk individuals improve their lifestyle (e.g., diet, exercise, smoking\u002Falcohol use), increase their knowledge about colorectal cancer, and strengthen their confidence and motivation to stay healthy.\n\nStudy Groups Participants in this study will be randomly assigned (like flipping a coin) to one of two groups:\n\n1. The Intervention Group: This group will take part in the 12-week health promotion program.\n2. The Control Group: This group will receive general health information or standard care but will not participate in the special program.\n\nProcedures The program for the Intervention Group includes:\n\n* Educational Workshops: Five in-person group sessions to learn about cancer prevention, create personal health plans, and solve problems with others.\n* Online Support: Regular health articles and tips sent through a private WeChat group.\n* Daily Check-ins: Using the WeChat group for simple daily check-ins on exercise, fruit\u002Fvegetable intake, and smoking\u002Falcohol use to build habit.\n* Peer Support: Being paired with a \"health buddy\" and interacting with other participants for motivation.\n\nAll participants will be asked to complete several questionnaires at the beginning of the study, during the program, and after it ends (at 3 months) to measure their knowledge, beliefs, and lifestyle habits.\n\nDuration The active program lasts for 12 weeks.\n\nPotential Benefits Participants in the Intervention Group may benefit from improved health habits, a better understanding of how to reduce their cancer risk, and increased social support. Participants in the control group will receive general health information. If they wish, they will receive the same health materials and behavioral change intervention as the intervention group after the intervention concludes.",[222,223,224],"Health Behavior","Colorectal Neoplasms","Primary Prevention\u002FMethods",[226],"Health Promotion；Health Behavior；Lifestyle Intervention；High-Risk Population","2025-11-28",{"date":229,"type":40},"2025-12-04",{"date":231,"type":40},"2025-11-10",{"date":233,"type":21},"2026-02-10",{"name":45,"class":46},{"id":236,"slug":4,"hasResults":10,"nctId":237,"briefTitle":238,"officialTitle":239,"acronym":4,"eligibilityCriteria":240,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":18,"enrollmentInfo":241,"targetDuration":4,"studyType":22,"phases":243,"briefSummary":244,"conditions":245,"keywords":249,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":4},"100602058","NCT07118566","Hyperthermia Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Gastrointestinal Malignancies With Liver Metastases","Hyperthermia Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Gastrointestinal Malignancies With Liver Metastases: A Multicenter, Open-label, Dual-cohort Phase II Exploratory Clinical Study","Inclusion Criteria:\n\n* Age between 18 and 75 years, male or female.\n* Histologically or cytologically confirmed diagnosis of gastrointestinal malignancy with liver metastases.\n* Prior treatment requirements:\n\nGastric cancer patients must have received at least one prior line of systemic therapy.\n\nColorectal cancer patients must have received at least two prior lines of systemic therapy.\n\n* Clinically assessed as suitable for hyperthermia combined with immune checkpoint inhibitor therapy.\n* At least one measurable lesion meeting RECIST 1.1 criteria.\n* Expected survival ≥6 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n* Adequate organ and bone marrow function.\n* Willingness to provide sufficient baseline and post-treatment samples, ability to comply with long-term follow-up and evaluation, and signed informed consent.\n* No prior history of other malignancies.\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Any comorbidities or underlying medical conditions that, in the investigator's judgment, render the patient unsuitable for study participation.\n* Presence of other severe physical or psychiatric disorders, or clinically significant laboratory abnormalities that may increase the risk associated with study participation, interfere with study results interpretation, or otherwise make the patient inappropriate for inclusion as determined by the investigator.",{"count":242,"type":21},40,[107],"This study aims to explore the synergistic antitumor effects and safety of hyperthermia combined with immune checkpoint inhibitors (ICIs) in patients with advanced gastrointestinal malignancies with liver metastases. Liver metastasis represents a common cause of treatment failure in gastrointestinal cancers, and the response rate to ICIs remains suboptimal in certain patients with liver metastases, potentially attributable to the immunosuppressive hepatic microenvironment. The combination of hyperthermia with ICIs, chemotherapy, or other therapeutic modalities may further enhance treatment efficacy. Hyperthermia could potentially reverse immunosuppression and improve ICI effectiveness through mechanisms including enhanced tumor blood perfusion, promoted antigen presentation, and increased immune cell infiltration. This multicenter, open-label, dual-cohort phase II trial will evaluate patients stratified by tumor type (colorectal cancer versus gastric cancer) to assess the objective response rate (ORR), progression-free survival (PFS), and safety profile of hyperthermia-ICI combination therapy. Concurrently, dynamic monitoring of peripheral immune markers (such as neutrophil-to-lymphocyte ratio and interleukins) and tumor microenvironment alterations will be conducted to identify potential predictive biomarkers, thereby providing preliminary evidence for subsequent phase III investigations. The ultimate objective is to develop more effective combination treatment strategies for patients with advanced gastrointestinal malignancies accompanied by liver metastases.",[246,247,248],"Gastrointestinal Cancer","Immunotherapy","Liver Metastasis",[250,251,198,252],"gastrointestinal cancer","immunotherapy","hyperthermia","2025-08-07",{"date":255,"type":40},"2025-08-12",{"date":257,"type":21},"2025-08-15",{"date":259,"type":21},"2029-09",{"name":45,"class":46},{"id":262,"slug":4,"hasResults":10,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":4,"eligibilityCriteria":266,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":18,"enrollmentInfo":267,"targetDuration":4,"studyType":22,"phases":268,"briefSummary":269,"conditions":270,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":96},"100595587","NCT07034391","A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status","A Phase II Single-Arm Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status","Inclusion Criteria:\n\n* Histologically or cytologically confirmed locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)\n* Documented negative for EGFR\u002FALK\u002FROS1\u002FBRAFV600E\u002FRET\u002FMETex14 mutations by validated genomic testing, with no prior targeted therapy and no history of other malignancies\n* No previous systemic therapy for advanced\u002Fmetastatic disease\n* At least one measurable lesion per RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1\n* No use of parathyroid hormone\u002Fderivatives, calcitonin, osteoprotegerin, mithramycin, or potassium supplements within the past 6 months\n* Adequate organ and marrow function\n\nExclusion Criteria:\n\n* Histologically or cytologically confirmed combined small cell and non-small cell lung cancer (mixed histology)\n* Any previous systemic anticancer treatment for NSCLC, including chemotherapy, biologics, immunotherapy, or investigational agents\n* Prior use of denosumab or any bone-modifying agents (e.g., bisphosphonates)\n* Uncontrolled hypocalcemia or hypophosphatemia\n* History or current evidence of osteonecrosis of the jaw (ONJ) or osteomyelitis of the jaw",{"count":242,"type":21},[107],"This is an interventional study to explore the efficacy and safety of denosumab combined chemotherapy and anti-PD-1\u002FPD-L1 inhibitor in locally advanced or metastatic NSCLC.",[271],"Non-Small Cell Lung Cancer","2025-06-22",{"date":274,"type":40},"2025-06-24",{"date":276,"type":40},"2025-05-12",{"date":278,"type":21},"2027-10-31",{"name":45,"class":46},{"id":281,"slug":4,"hasResults":10,"nctId":282,"briefTitle":283,"officialTitle":284,"acronym":285,"eligibilityCriteria":286,"healthyVolunteers":214,"sex":16,"minAge":215,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":96},"100592299","NCT06991621","The Effect of Situation Puzzle Games on Nursing Students' Death Anxiety and Meaning in Life","Mechanisms and Design Framework Study of Gamified Education in Professional Identity Formation for Medical Undergraduates","SPGI","Inclusion Criteria:\n\n* Third-year full-time undergraduate nursing students\n* Completed clinical observation training but not yet entered clinical internship phase\n* Aged ≥18 years\n* Provide informed consent and voluntarily participate in the study\n\nExclusion Criteria:\n\n* Participated in similar death education interventions within the past 3 months\n* Diagnosed with severe mental or psychological disorders\n* Currently on a leave of absence (academic or personal)",{"count":288,"type":21},70,[24],"Goal of this interventional study\n\nThe purpose of this research is to investigate the effects of a scenario-based puzzle educational game on death anxiety and meaning in life among nursing students. It aims to answer the following key questions:\n\nCan the scenario-based puzzle educational game enhance nursing students' sense of meaning in life?\n\nCan the scenario-based puzzle educational game reduce death anxiety in nursing students?\n\nWhat are nursing students' experiences and perceptions of this educational game?\n\nStudy design Researchers will compare the intervention group (participating in the game) with a control group (receiving death education manuals) to evaluate the effectiveness of the game-based intervention.\n\nParticipants will:\n\nBe recruited through campus posters\n\nBe randomly assigned to either the intervention or control group and complete baseline questionnaires\n\nIn the control group: Receive death education manuals twice weekly for 3 weeks\n\nIn the intervention group: Participate in group sessions (5 students per group) to play the scenario-based puzzle game twice weekly for 3 weeks\n\nComplete follow-up questionnaires and participate in qualitative interviews regarding their experiences with manual-based education or the game intervention after the 3-week intervention period",[292],"Death Anxiety","2025-05-18",{"date":295,"type":40},"2025-05-28",{"date":297,"type":40},"2025-04-21",{"date":299,"type":21},"2025-08-21",{"name":45,"class":46},{"id":302,"slug":4,"hasResults":10,"nctId":303,"briefTitle":143,"officialTitle":143,"acronym":4,"eligibilityCriteria":304,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":305,"targetDuration":4,"studyType":22,"phases":306,"briefSummary":148,"conditions":307,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":312,"leadSponsor":313,"locationsCount":96},"100589240","NCT06951841","Inclusion Criteria:\n\n1. Volunteer to join the study, sign the informed consent and sign the date, have good compliance, and cooperate with follow-up\n2. Age≥18 years\n3. Diagnosis of extensive stage small cell lung cancer (ES-SCLC) confirmed histologically or pathologically (according to American Veterans Lung Cancer Association, VALG staging)\n4. ECOG 0-2\n5. Subjects had not received any systemic treatment for ES-SCLC in the past (including chemotherapy, use of similar VEGFR inhibitors and immune checkpoint inhibitors, etc.)\n6. Subjects with limited-stage small cell lung cancer (LS-SCLC) have received radiotherapy, chemotherapy, or chemoradiotherapy for more than 6 months\n7. Expected survival ≥ 3 months\n8. Must have measurable target lesions that meet RECIST1.1 criteria (CT scan length of tumor lesion \\>10mm); In patients with initial asymptomatic brain metastases, craniocerebral radiotherapy may be performed during induction chemotherapy\n9. If the major organs are functioning normally, the following criteria are met:\n\n   1. Blood routine examination must meet (no blood transfusion within 14 days, no hematopoietic factor and no drug correction) : ANC ≥ 1.5×10\\^9\u002FL; HB ≥ 90 g\u002FL; PLT ≥ 100×10\\^9\u002FL\n   2. Biochemical examination must meet the following criteria: TBIL ≤ 1.5ULN; ALT and AST≤ 2.5ULN;\n   3. Renal function must meet the following criteria: serum creatinine (Cr) ≤1.5×ULN, or creatinine clearance ≥40 mL\u002Fmin (using the standard Cockcroft-Gault formula)\n   4. Coagulation function must meet: INR≤1.5 and APTT≤1.5ULN\n10. Female who are fertile must have a serum or urine pregnancy test within 72 hours before the first medication and the result is negative. Fertile female and male subjects whose partners are fertile female must agree to a highly effective method of avoiding and breastfeeding during the study period until 90 days after the last dose of the study drug. The investigator or designee, in consultation with the subject, shall confirm that the subject understands the proper and consistent use of contraceptive methods\n11. For males, they should be surgically sterilized or consent to a highly effective method of avoidance during the trial and for 90 days after the last administration of the experimental drug\n12. Female participants had to agree not to breastfeed during the study period or for 180 days after the last dose of study treatment\n\nExclusion Criteria:\n\n1. Patients with meningeal metastases or symptomatic brain metastases\n2. Previous T cell co-stimulation or immune checkpoint therapy, including but not limited to cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors, PD-1 inhibitors, PD-L1\u002F2 inhibitors, CD137 agonists, or other targeting T cell drugs;\n3. Past treatment with anlotinib\n4. Factors affecting oral medication, such as inability to swallow, post-GI resection, chronic diarrhea, intestinal obstruction, etc\n5. Uncontrollable pleural effusion or ascites\n6. Have any active autoimmune disease or history of autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (may be included after hormone replacement therapy), tuberculosis); Patients with skin conditions (such as vitiligo, psoriasis, or alopecia) that have been in complete remission from childhood asthma and do not require any intervention in adulthood and do not require systemic treatment may be included. Patients who require medical intervention with bronchodilators may not be included\n7. Patients with congenital or acquired immunodeficiency, such as human immunodeficiency virus (HIV) infection, active hepatitis B (HBV DNA ≥ 500IU\u002Fml), hepatitis C (HCV antibody positive and HCV-RNA above the lower detection limit of analytical methods), or co-infection with hepatitis B and hepatitis C\n8. Urine routine suggests urinary protein ≥(++), or 24h urinary protein ≥2g or severe hepatic and renal insufficiency\n9. Patients requiring systemic therapy with corticosteroids (\\>10mg\u002F day of prednisone or equivalent) or other immunosuppressants within 14 days prior to initial medication. In the absence of active autoimmune disease, inhaled or topical corticosteroids are permitted, as well as adrenal hormone replacement therapy at doses \\>10 mg\u002F day of prednisone efficacy\n10. Patients who have been treated with anti-tumor vaccine or other immunostimulating anti-tumor agents (interferon, interleukin, thymosin, immunocell therapy, etc.) within 1 month prior to initial medication\n11. Other malignant neoplasms were present within 5 years prior to admission, except for adequately treatable carcinoma in situ of the cervix, basal cell or squamous cell skin cancer, local prostate cancer after radical surgery, and ductal carcinoma in situ after radical surgery\n12. There is evidence of past or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiological pneumonia, drug-induced pneumonia, radiologically proven active pneumonia, and severe impairment of lung function\n13. Uncontrolled hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90mmHg, despite optimal medical treatment\n14. Patients with grade II or higher myocardial ischemia or myocardial infarction and poorly controlled arrhythmias (including QTc interval ≥450ms in men and ≥470ms in women). According to the NYHA criteria, patients with grade III to Ⅳ cardiac insufficiency, or those with left ventricular ejection fraction (LVEF) \\\u003C 50% indicated by color Doppler ultrasound had myocardial infarction in the 6 months prior to enrollment, heart failure of New York Heart Society grade II or above, uncontrolled angina, uncontrolled severe ventricular arrhythmia, clinically significant pericardial disease, and myocardial infarction. Or electrocardiogram suggests acute ischemia or abnormal active conduction system\n15. Concurrent severe infection within 4 weeks prior to first dosing, or unexplained fever \\>38.5°C during screening\u002Fprior to first dosing\n16. Major surgery, open biopsy, or significant trauma were performed within 28 days prior to enrollment\n17. Aortic\u002Fvenous thrombosis occurred within 6 months\n18. The researchers assessed possible risk of severe hemoptysis, bleeding events, or wearing\n19. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation\n20. Pregnant or lactating women; Fertile patients who are unwilling or unable to use effective contraception\n21. Allergic reaction to any investigational drug or its ingredients\n22. Any condition that the investigator believes is likely to harm the subject or cause the subject to be unable to meet or perform the study requirements",{"count":146,"type":21},[128],[150],"2025-04-23",{"date":310,"type":40},"2025-04-30",{"date":310,"type":21},{"date":161,"type":21},{"name":45,"class":46},{"id":315,"slug":4,"hasResults":10,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":323,"conditions":324,"keywords":329,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":4},"100583798","NCT06881017","Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping","Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping: an Umbrella Phase II Exploratory Clinical Study","Inclusion Criteria:\n\n1. Age ≥18 years, regardless of gender;\n2. Histologically or pathologically confirmed gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction;\n3. Advanced or metastatic disease with no prior systemic therapy for advanced-stage disease (Patients who relapsed \\>6 months after completing neoadjuvant\u002Fadjuvant therapy are eligible, with prior neoadjuvant\u002Fadjuvant regimens not counted as prior lines of therapy);\n4. At least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST v1.1);\n5. Archival or fresh tumor tissue sample available for biomarker testing (HER2, CLDN18.2, and PD-L1 expression);\n6. ECOG performance status: 0-1;\n7. Life expectancy ≥12 weeks;\n8. Adequate organ and bone marrow function meeting the following criteria:\n\n   1. Hemoglobin ≥90 g\u002FL (no blood transfusion within 14 days);\n   2. Absolute neutrophil count (ANC) ≥1.5×10⁹\u002FL;\n   3. Platelet count ≥90×10⁹\u002FL;\n   4. Total bilirubin ≤1.5×upper limit of normal (ULN);\n   5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN if liver metastases are present);\n   6. Serum creatinine ≤1.5×ULN;\n   7. Left ventricular ejection fraction (LVEF) ≥50% by echocardiography; QTc interval \\\u003C450 ms for males and \\\u003C470 ms for females;\n9. Coagulation parameters:\n10. For patients not on anticoagulation therapy: INR ≤1.5 and activated partial thromboplastin time (APTT) ≤1.5×ULN;\n11. For patients receiving full-dose or parenteral anticoagulation: Stable anticoagulant dose for ≥2 weeks prior to enrollment, with coagulation tests within the therapeutic range;\n12. Contraception requirements:\n13. Women of childbearing potential must have a negative pregnancy test (serum or urine) within 14 days prior to enrollment and agree to use effective contraception during the study and for 3 months after the last dose;\n14. Men must be surgically sterile or agree to use effective contraception during the study and for 3 months after the last dose;\n15. Recovery from prior therapy-related toxicities to ≤Grade 1 (surgical wounds must be fully healed if applicable);\n16. Voluntary participation with signed informed consent form and anticipated adherence to protocol requirements.\n\nExclusion Criteria:\n\n1. History of gastrointestinal perforation and\u002For fistula within 6 months prior to treatment, or active gastrointestinal bleeding within 3 months;\n2. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage;\n3. Known history of hypersensitivity to any component of the investigational drug(s) or excipients;\n4. Prior treatments meeting any of the following:\n\n   1. Received any investigational drug within 4 weeks prior to the first dose of the study drug or within 5 half-lives of the last investigational agent (whichever is shorter);\n   2. Concurrent enrollment in another interventional clinical study (observational or follow-up studies are permitted);\n   3. Received antitumor therapy (including radiotherapy, chemotherapy, immunotherapy, endocrine therapy, targeted therapy, biologics, or tumor embolization) within 2 weeks prior to the first dose of the study drug;\n5. History of leptomeningeal metastasis or current active brain metastases;\n6. Severe infection (CTCAE v5.0 Grade \\>2) within 4 weeks prior to the first dose of the study drug (e.g., pneumonia requiring hospitalization, bacteremia, or septic complications); active pulmonary inflammation on baseline chest imaging, or signs\u002Fsymptoms of infection requiring oral\u002FIV antibiotics within 2 weeks prior to the first dose (prophylactic antibiotics excluded);\n7. History of interstitial lung disease (except radiation pneumonitis without steroid treatment or non-infectious pneumonitis);\n8. Active tuberculosis (TB) infection confirmed by medical history or CT scan, history of active TB within 1 year prior to enrollment, or untreated active TB diagnosed \\>1 year prior to enrollment;\n9. Diagnosis of another malignancy within 5 years prior to the first dose of the study drug, except malignancies with low metastatic\u002Flethal risk (5-year survival rate \\>90%), such as adequately treated basal cell carcinoma, squamous cell skin cancer, or carcinoma in situ of the cervix;\n10. Pregnant or lactating women;\n11. Other conditions deemed by the investigator to jeopardize subject safety or trial integrity, including severe comorbidities (e.g., psychiatric disorders), clinically significant laboratory abnormalities, or social\u002Ffamily factors that may compromise protocol adherence or data collection.",{"count":321,"type":21},140,[107],"This study is a prospective, umbrella-design, Phase II clinical trial. Eligible participants with advanced or metastatic gastric cancer who are treatment-naïve for advanced-stage systemic therapy will undergo biomarker profiling (HER2, CLDN18.2, and PD-L1) via next-generation sequencing (NGS) or immunohistochemistry (IHC). Participants will be stratified into distinct molecular subtypes and assigned subtype-specific therapeutic regimens. The primary objectives are to assess treatment efficacy (e.g., objective response rate) and safety profiles across molecularly defined cohorts.",[325,326,327,328],"Gastric Cancer","HER2 + Gastric Cancer","CLDN18.2-positive Adenocarcinoma of the Gastroesophageal Junction","PD-L1 Positive",[330,331,332,333],"gastric cancer","HER2","CLDN18.2","PD-L1","2025-03-17",{"date":336,"type":40},"2025-03-18",{"date":338,"type":21},"2025-05-01",{"date":340,"type":21},"2029-11-01",{"name":45,"class":46},{"id":343,"slug":4,"hasResults":10,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":124,"enrollmentInfo":348,"targetDuration":4,"studyType":22,"phases":350,"briefSummary":351,"conditions":352,"keywords":4,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":362},"100561813","NCT06595043","Effects of Different Occlusion Angles of Disposable Tracheal Blocker on Right One-lung Ventilation","Effects of Different Occlusion Angles of Disposable Tracheal Blocker on Right One-lung Ventilation: a Multi-center, Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n* Age ranged from 18 to 65 years old;\n* American Society of Anesthesiologists (ASA) grade I-III;\n* No history of drug allergy or abnormal anesthesia;\n* Patients undergoing right thoracoscopic surgery;\n* The preoperative oxygen saturation was not less than 94%.\n\nExclusion Criteria:\n\n* Patients with a history of acute lung injury or ARDS within 3 months;\n* Cardiac function class IV (New York Heart Association classification);\n* Chronic renal failure (renal cell filtration rate \\\u003C30ml min-11.73m-2), severe liver disease;\n* Patients with blurred consciousness and cognitive dysfunction;\n* Patients with severe coagulation dysfunction;\n* Without preoperative oxygen inhalation, blood oxygen \\\u003C94%, severe pulmonary dysfunction;\n* Patients with endotracheal tube admitted to ICU after operation;\n* Body mass index (BMI) \\>30;\n* Patients who had had lung surgery；\n* Inability to complete the study;",{"count":349,"type":21},96,[24],"This trial is a practical, multicenter, prospective, parallel grouping, randomized controlled,two-arm study. This study will be conducted in three centers including the First Hospital of China Medical University, Seoul National University Hospital and the University Clinical Center of Serbia. The investigators aim to investigate the effect of different occlusion angles of disposable tracheal blocker on right one-lung ventilation",[353],"The Direction of Blocker Placement","2024-09-12",{"date":356,"type":40},"2024-09-19",{"date":358,"type":21},"2024-10-09",{"date":360,"type":21},"2025-12-31",{"name":45,"class":46},3,{"id":364,"slug":4,"hasResults":10,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":367,"eligibilityCriteria":368,"healthyVolunteers":10,"sex":369,"minAge":76,"maxAge":124,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":372,"briefSummary":373,"conditions":374,"keywords":376,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":96},"100385793","NCT04303325","Effect of Esketamine on Postoperative Depression、Gut Microbiota、Bispectral Index Data of Depression Patients Undergoing Breast Cancer Operation (ESPOD-BI)","ESPOD-BI","Inclusion Criteria:\n\n* At least18 years and pre-menopausal;\n* scheduled to undergo elective breast cancer operation;\n* American Society of Anaesthesiologists (ASA) risk classification I-II.\n* Montgomery-asberg Depression Rating Scale (MADRS) score ≥22\n\nExclusion Criteria:\n\n* Cognitive difficulties\n* Partial or complete gastrectomy\n* Previous esophageal surgery\n* Inability to conform to the study's requirements\n* Ongoing participation or participation in another study \\\u003C1 month ago","FEMALE",{"count":371,"type":21},72,[128],"This study is a prospective, randomized, controlled (randomized, parallel group, concealed allocation), double-blinded trial. All depression patients undergoing breast cancer operation will be randomized 1:1 to the treatment intervention with general anesthesia as an adjunct to esketamine or saline. The objective of the trial is to evaluate the postoperative depression、gut microbiota、bispectral index data of patients undergoing breast cancer operation with esketamine or saline.",[375],"Depression",[377,378,379,380],"depression","sleep deprivation","gut microbiota","bispectral index","2024-07-18",{"date":383,"type":40},"2024-07-22",{"date":385,"type":40},"2021-10-08",{"date":387,"type":21},"2024-12-30",{"name":45,"class":46},{"id":390,"slug":4,"hasResults":10,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":187,"enrollmentInfo":395,"targetDuration":4,"studyType":22,"phases":397,"briefSummary":398,"conditions":399,"keywords":401,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":96},"100523851","NCT06101082","A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors","An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With HER2+ Locally Advanced and\u002F or Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Patients should understand and sign informed consent forms and voluntarily participate in clinical studies;\n2. Age≥ 18, \\\u003C 70 years old, gender is not limited;\n3. Locally advanced and\u002For metastatic solid tumors; HER2-positive expression in tumor tissues (staining 3+, or staining 2+ with HER2 gene amplification should be further performed by ISH and other methods) ;\n4. Histology-confirmed solid tumors (breast cancer,gastric cancer, colorectal cancer, pancreas cancer, etc.), conventional treatment is ineffective or Intolerability conventional treatment or lack of effective treatment;\n5. According to RECIST v 1.1, at least one measurable lesion with a maximum lesion diameter not exceeding 6 cm;\n6. Expected survival≥ 12 weeks;\n7. ECOG score≤ 2 ;\n8. Adequate hematological function ; have no performed blood transfusion or received cell growth factor within 7 days before screening hematological evaluation:Neutrophil ≥ 1.0×10\\^9\u002FL;Hemoglobin≥ 80g\u002FL;Platelet ≥ 75×10\\^9\u002FL;Lymphocytes ≥ 0.5×10\\^9\u002FL\n9. Adequate liver function: serum total bilirubin ≤1.5× ULN (excluding Gilbert's syndrome); AST and ALT≤2.5×ULN( AST and ALT ≤5×ULN with liver metastasis);\n10. Adequate renal function: creatinine ≤1.5× ULN or endogenous creatinine clearance ≥50 mL\u002Fmin;\n11. LVEF ≥ 50%;\n12. There was no evidence that subjects had difficulty breathing at rest or pulse oximetry\\>90% when breathing indoor air;\n13. Sufficient intravenous access for apheresis; no other contraindications to blood cell separation;\n14. The pregnancy test for women of childbearing age must be negative. All subjects must agree to take effective contraception from the signing of the informed consent to 6 months after the last dose of the study drug infusion.\n\nExclusion Criteria:\n\n1. Previously using any CAR-T cell products or other genetically modified T cell therapies;\n2. Patients who are waiting for organ transplantation or with a history of allogeneic stem cell or solid organ transplantation;\n3. Patients with acute or uncontrolled active infection, including but not limited to active tuberculosis;\n4. Patients with Hepatitis B infection (HBV surface antigen positive and\u002For hepatitis B core antibody positive and hepatitis B DNA \\>10\\^3 copies \u002FmL) ; hepatitis C infection(hepatitis C antibodies positive) ; Syphilis infection (antibody positive), HIV infection (antibody positive);\n5. Patients with hyponatremia and\u002For hypokalemia, blood sodium \\\u003C125mmol\u002FL and\u002For blood potassium\\\u003C3.5mmol\u002FL (Sodium and\u002For potassium supplementation may be given before participating in the study to restore blood sodium and\u002For potassium above this level);\n6. Imaging results the proportion of liver replaced by tumor ≥50%;\n7. Patients who taken continuous systemic steroids within 14 days before apheresis or within 72 hours before cell therapy (prednisone\\> 5 mg\u002Fday or equivalent dose of other hormones), excepting for those who use inhaled Steroid hormones;\n8. Systemic sexualization is accepted 2 weeks before apheresis or 5 half-lives (whichever is shorter). Toxicity to previous antineoplastic therapy has not recovered (based on CTCAE version 5.0 assessment); excepting for alopecia, pigmentation and other tolerable events judged by the investigator or permitted laboratory 9.abnormalities according to the protocol;\n9. Antibody therapy within 4 weeks before apheresis and preconditioning;\n10. Anti-PD-1\u002FPD-L1 monoclonal antibody therapy within 4 weeks before apheresis and preconditioning;\n11. Immunostimulation or immunosuppressive therapy within 28 days prior to apheresis;\n12. Radiotherapy within 28 days prior to apheresis, except limited local palliative radiotherapy;\n13. Patients with other malignant tumors within the past 5 years or at the present (except for basal cell carcinoma of the skin, breast\u002Fcervix Carcinoma in situ and other malignant tumors that have not been treated in the past five years have been effectively controlled);\n14. Patients with active ulcers or active gastrointestinal bleeding that are difficult to control;\n15. Patients with previous medical history of central nervous system (CNS) primary or metastatic tumors including meningeal metastases, unless previously treated for brain metastases, who are currently asymptomatic, and do not need steroid or enzyme-inducing antiepileptic drug treatment within 14 days before screening;\n16. Patients with other central nervous system diseases that may affect the safety of the subjects as judged by the researchers (such as epileptic seizures, cerebral hemorrhage, dementia, etc.);\n17. Patients with uncontrolled hypertension, unstable angina, NYHA III or higher-grade congestive heart failure with an ejection fraction of the heart below 50%, or an ECG with significant abnormalities, serious arrhythmias requiring treatment and medical history of myocardial infarction within 6 months prior to initiation of study treatment;\n18. Patients with severe respiratory diseases before apheresis, such as interstitial lung disease, active pulmonary tuberculosis;\n19. Patients with active or past autoimmune diseases that may relapse (such as systemic lupus erythematosus, rheumatoid arthritis, etc.), except for the following diseases: type 1 diabetes, hypothyroidism that only needs hormone replacement therapy, skin diseases that do not require systemic therapy (such as vitiligo, psoriasis or hair loss);\n20. Any serious or uncontrollable systemic disease, systemic Complications, other serious concurrent diseases (such as hemophagocytic syndrome, etc.), special cases of tumor conditions according to the investigator's judgment that may make patients unsuitable for entry into the study or affect compliance with the protocol, or significant interference with the correct assessment of drug safety, toxicity, and effectiveness;\n21. Received any major surgery within 4 weeks before apheresis (except exploratory laparotomy or laparoscopy exploration) or severe trauma; Any major surgery during the DLT observation period, or has not yet completely recovered from any previous invasive procedure;\n22. Patient allergic or intolerant to the preconditioning drugs that may be used in the research process or the drugs for symptomatic treatment of CRS , including but not limited to fludarabine and cyclophosphamide or tocilizumab;Known hypersensitivity to the components of anti-HER2-CAR-T; or have any history of severe allergies, for example, anaphylactic shock;\n23. Patients who have participated in other interventional clinical trials within 1 month before administration;\n24. Pregnant or lactating women;\n25. Patients of childbearing age who are unwilling or unable to use reliable contraception during the study period;\n26. Patients who are unable or unwilling to comply with clinical protocols as judged by the investigator;\n27. Persons involved in the study plan and execution.",{"count":396,"type":21},9,[191],"This is a single-center, open-label clinical study of anti-HER2-CAR-T cells for HER2+ patients with locally advanced and\u002For metastatic solid tumors. In this study, a single-dose regimen was designed, and the investigator had the discretion to decide whether the patient received more than once CAR T-cell therapy.This study intends to include HER2+ patients with locally advanced and\u002For metastatic solid tumors.They will take the anti-HER2-CAR-T cell transfusion after a screening period, mononuclear cell (PBMC) collection, bridging therapy if necessary, and lymphocyte clearance pretreatment period.",[400],"Solid Tumor",[402,403,404,331],"CAR-T","solid tumor","Cell therapy","2024-03-05",{"date":407,"type":40},"2024-03-06",{"date":409,"type":40},"2024-01-16",{"date":411,"type":21},"2026-10-19",{"name":45,"class":46},{"id":414,"slug":4,"hasResults":10,"nctId":415,"briefTitle":416,"officialTitle":417,"acronym":4,"eligibilityCriteria":418,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":22,"phases":420,"briefSummary":421,"conditions":422,"keywords":424,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":4},"100537845","NCT06283121","A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer","A Clinical Study to Evaluate the Safety and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Combination With SOX and Toripalimab in Patients With Peritoneal Metastases From Gastric Cancer","Inclusion Criteria:\n\n1. Male or female, age≥ 18 years；\n2. Patients with a diagnosis of gastric cancer by histopathology or cytology, accompanied by peritoneal metastasis, without systemic therapy, or for patients who have received neoadjuvant\u002Fadjuvant chemotherapy before, the time from last treatment to disease recurrence \\> 6 months;\n3. Tumor Her2 negative (IHC 0\u002F1＋ or IHC 2＋ and FISH-).\n4. At least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors （RECIST) 1.1;\n5. WBC≥3.0×10\\^9 \u002FL; ANC≥1.5×10\\^9 \u002FL; HB≥90 g\u002FL; PLT≥75×10\\^9 \u002FL;\n6. ALT and AST≤3×ULN (≤5×ULN with liver metastasis); ALB≥20g\u002FL; Cr≤1.5×ULN or CCr\\>50 mL\u002Fmin; TBIL≤1.5×ULN; APTT≤1.5×ULN and INR or PT≤1.5×ULN (without anticoagulation therapy)\n7. LVEF≥50%; male QTc≤450 mms, female QTc≤470 mms;\n8. ECOG 0\\~1；\n9. Expected survival ≥ 3 months;\n10. Consent to contraception；\n11. Understand and voluntarily sign a written ICF and be willing to comply with all trial requirements.\n\nExclusion Criteria:\n\n1. History of other malignancies (except cured basal cell skin cancer, cervical carcinoma in situ etc.) within 5 years before study drug administration;\n2. Patients with central nervous system metastases with clinical symptoms;\n3. Patients who have been treated with high-dose systemic corticosteroids (prednisone \\> 10 mg\u002Fday or equivalent doses) or other immunosuppressants within 2 weeks before the first dose of BioTTT001;\n4. Previous treatment with other adenovirus drugs within 28 days before the first dose of BioTTT001;\n5. Patients who have undergone any major surgery (except needle biopsy, etc.) or severe trauma within 14 days before the first dose of BioTTT001;\n6. Patients who have not recovered from the adverse reactions of previous treatments (the treatment-related toxicity ≤ grade 2, except for alopecia );\n7. Patients with primary immunodeficiency;\n8. Patients with active autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, etc.), except type 1 diabetes, hypothyroidism that only needs hormone replacement therapy, and skin diseases that do not need systemic treatment (such as vitiligo, psoriasis or alopecia);\n9. Patients with active infection requiring systemic anti-infective therapy;\n10. HBsAg positive, and blood HBV DNA≥100 IU\u002FmL; anti-HCV positive; HIV positive; active syphilis;\n11. Patients with active tuberculosis or drug-induced interstitial lung disease；\n12. Patients with active inflammatory bowel disease ；\n13. NYHA≥ grade 3；\n14. Known allergy to the investigational drug or its components;\n15. Patients with prior organ transplants;\n16. Pregnant or lactating women;\n17. Other reasons judged by the investigator.",{"count":105,"type":21},[107],"This is a phase I, single arm, open-label clinical study of BioTTT001 in combination with SOX and Toraplizumab in patients with peritoneal metastases from gastric cancer.",[423],"Gastric Cancer, Metastatic",[196,425,330,426],"IL-12","peritoneal metastases","2024-02-27",{"date":429,"type":40},"2024-02-29",{"date":431,"type":21},"2024-04-02",{"date":433,"type":21},"2027-11-30",{"name":45,"class":46},{"id":436,"slug":4,"hasResults":10,"nctId":437,"briefTitle":438,"officialTitle":438,"acronym":4,"eligibilityCriteria":439,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":187,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":441,"briefSummary":442,"conditions":443,"keywords":445,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":96},"100517097","NCT06013111","An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti-CEA-CAR-T Cells Injection in Patients With CEA+ Locally Advanced and\u002For Metastatic Solid Tumors","Inclusion Criteria:\n\n1. Patients should understand and sign informed consent forms and voluntarily participate in clinical studies;\n2. Age≥ 18, \\\u003C 70 years old, gender is not limited;\n3. Locally advanced and\u002For metastatic solid tumors; Cytoplasmic and\u002For membranous high CEA expression in tumor tissue is required (expression intensity of 2+ and above on the area ≥50%) ;\n4. Histology-confirmed solid tumors (gastric cancer, colorectal cancer, esophageal cancer, small bowel cancer, pancreas adenocarcinoma and other digestive system tumors are predominant), conventional treatment is ineffective or Intolerability conventional treatment or lack of effective treatment;\n5. According to RECIST v 1.1, at least one measurable lesion with a maximum lesion diameter not exceeding 6 cm;\n6. Expected survival≥ 12 weeks;\n7. ECOG score≤ 2 ;\n8. Adequate hematological function ; have no performed blood transfusion or received cell growth factor within 7 days before screening hematological evaluation:\n\n   * Neutrophil ≥ 1.0×10\\^9\u002FL\n   * Hemoglobin≥ 80g\u002FL\n   * Platelet ≥ 75×10\\^9\u002FL\n   * Lymphocytes ≥ 0.5×10\\^9\u002FL\n9. Adequate liver function: serum total bilirubin ≤1.5× ULN (excluding Gilbert's syndrome); AST and ALT≤2.5×ULN；( AST and ALT ≤5×ULN with liver metastasis)\n10. Adequate renal function: creatinine ≤1.5× ULN or endogenous creatinine clearance ≥50 mL\u002Fmin;\n11. LVEF ≥ 50%;\n12. There was no evidence that subjects had difficulty breathing at rest or pulse oximetry\\>90% when breathing indoor air;\n13. Sufficient intravenous access for apheresis; no other contraindications to blood cell separation;\n14. The pregnancy test for women of childbearing age must be negative. All subjects must agree to take effective contraception from the signing of the informed consent to 6 months after the last dose of the study drug infusion.\n\nExclusion Criteria:\n\n1. Previously using any CAR-T cell products or other genetically modified T cell therapies;\n2. Patients who are waiting for organ transplantation or with a history of allogeneic stem cell or solid organ transplantation;\n3. Patients with acute or uncontrolled active infection, including but not limited to active tuberculosis;\n4. Patients with Hepatitis B infection (HBV surface antigen positive and\u002For hepatitis B core antibody positive and hepatitis B DNA \\>10\\^3 copies \u002FmL) ; hepatitis C infection(hepatitis C antibodies positive) ; Syphilis infection (antibody positive), HIV infection (antibody positive);\n5. Patients with hyponatremia and\u002For hypokalemia, blood sodium \\\u003C125mmol\u002FL and\u002For blood potassium\\\u003C3.5mmol\u002FL (Sodium and\u002For potassium supplementation may be given before participating in the study to restore blood sodium and\u002For potassium above this level);\n6. Imaging results the proportion of liver replaced by tumor ≥50%;\n7. Patients who taken continuous systemic steroids within 14 days before apheresis or within 72 hours before cell therapy (prednisone\\> 5 mg\u002Fday or equivalent dose of other hormones), excepting for those who use inhaled Steroid hormones;\n8. Systemic sexualization is accepted 2 weeks before apheresis or 5 half-lives (whichever is shorter). Toxicity to previous antineoplastic therapy has not recovered (based on CTCAE version 5.0 assessment); excepting for alopecia, pigmentation and other tolerable events judged by the investigator or permitted laboratory abnormalities according to the protocol;\n9. Antibody therapy within 4 weeks before apheresis and preconditioning;\n10. Anti-PD-1\u002FPD-L1 monoclonal antibody therapy within 4 weeks before apheresis and preconditioning;\n11. Immunostimulation or immunosuppressive therapy within 28 days prior to apheresis;\n12. Radiotherapy within 28 days prior to apheresis, except limited local palliative radiotherapy;\n13. Patients with other malignant tumors within the past 5 years or at the present (except for basal cell carcinoma of the skin, breast\u002Fcervix Carcinoma in situ and other malignant tumors that have not been treated in the past five years have been effectively controlled);\n14. Patients with active ulcers or active gastrointestinal bleeding that are difficult to control;\n15. Patients with previous medical history of central nervous system (CNS) primary or metastatic tumors including meningeal metastases, unless previously treated for brain metastases, who are currently asymptomatic, and do not need steroid or enzyme-inducing antiepileptic drug treatment within 14 days before screening;\n16. Patients with other central nervous system diseases that may affect the safety of the subjects as judged by the researchers (such as epileptic seizures, cerebral hemorrhage, dementia, etc.);\n17. Patients with uncontrolled hypertension, unstable angina, NYHA III or higher-grade congestive heart failure with an ejection fraction of the heart below 50%, or an ECG with significant abnormalities, serious arrhythmias requiring treatment and medical history of myocardial infarction within 6 months prior to initiation of study treatment;\n18. Patients with severe respiratory diseases before apheresis, such as interstitial lung disease, active pulmonary tuberculosis;\n19. Patients with active or past autoimmune diseases that may relapse (such as systemic lupus erythematosus, rheumatoid arthritis, etc.), except for the following diseases: type 1 diabetes, hypothyroidism that only needs hormone replacement therapy, skin diseases that do not require systemic therapy (such as vitiligo, psoriasis or hair loss);\n20. Any serious or uncontrollable systemic disease, systemic Complications, other serious concurrent diseases (such as hemophagocytic syndrome, etc.), special cases of tumor conditions according to the investigator's judgment that may make patients unsuitable for entry into the study or affect compliance with the protocol, or Significant interference with the correct assessment of drug safety, toxicity, and effectiveness;\n21. Received any major surgery within 4 weeks before apheresis (except exploratory laparotomy or laparoscopy exploration) or severe trauma; Any major surgery during the DLT observation period, or has not yet completely recovered from any previous invasive procedure;\n22. Patient allergic or intolerant to the preconditioning drugs that may be used in the research process or the drugs for symptomatic treatment of CRS , including but not limited to fludarabine and cyclophosphamide or tocilizumab;Known hypersensitivity to the components of anti-CEA-CAR-T; or have any history of severe allergies, for example, anaphylactic shock;\n23. Patients who have participated in other interventional clinical trials within 1 month before administration;\n24. Pregnant or lactating women;\n25. Patients of childbearing age who are unwilling or unable to use reliable contraception during the study period;\n26. Patients who are unable or unwilling to comply with clinical protocols as judged by the investigator;\n27. Persons involved in the study plan and execution.",{"count":396,"type":21},[191],"This is a single-center, open-label clinical study of anti-CEA-CAR-T cells for CEA+ patients with locally advanced and\u002For metastatic solid tumors. In this study, a single-dose regimen was designed, and the investigator had the discretion to decide whether the patient received more than once CAR T-cell therapy.This study intends to include CEA+ patients with locally advanced and\u002For metastatic solid tumors.They will take the anti-CEA-CAR-T cell transfusion after a screening period, mononuclear cell (PBMC) collection, bridging therapy if necessary, and lymphocyte clearance pretreatment period.",[444],"Carcinoma",[402,403,404,446],"CEA","2024-02-20",{"date":449,"type":40},"2024-02-21",{"date":451,"type":40},"2023-10-23",{"date":453,"type":21},"2026-09-01",{"name":45,"class":46},{"id":456,"slug":4,"hasResults":10,"nctId":457,"briefTitle":458,"officialTitle":459,"acronym":4,"eligibilityCriteria":460,"healthyVolunteers":214,"sex":16,"minAge":76,"maxAge":18,"enrollmentInfo":461,"targetDuration":4,"studyType":22,"phases":462,"briefSummary":463,"conditions":464,"keywords":467,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":475,"startDateStruct":477,"completionDateStruct":478,"leadSponsor":480,"locationsCount":96},"100525201","NCT06118658","Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR\u002FMSI-H or POLE\u002FPOLD1 Mutations","A Single-arm, Open, Multicenter Phase II Study of Chemotherapy-sequential Tislelizumab Adjuvant Therapy After Radical Resection in Patients With Gastric or Colorectal Adenocarcinoma With dMMR\u002FMSI-H or POLE\u002FPOLD1 Mutations","Inclusion Criteria:\n\n1.Be able to understand and voluntarily sign a written informed consent, which must be signed prior to performing the specified study procedure required for the study 2.Age and gender: ≥18 years old and≤75 years old, both men and women. 3.dMMR\u002FMSI-H or POLE\u002FPOLD1 gene mutation was confirmed by immunohistochemical PCR or NGS 4.0-1 physical fitness score by the Eastern United States Cancer Collaboration (ECOG)。 5. Expected survival is 12 weeks 6.Radical gastrectomy or enterectomy, including open surgery or laparoscopic surgery, to achieve R0 resection (no residual cancer at the margin) 7.According to the American Joint Committee on Cancer AJCC 8th Edition cancer stage, it was confirmed by histopathology as gastric adenocarcinoma or esophagogastric junction adenocarcinoma or intestinal adenocarcinoma, and the postoperative pathological stage of gastric adenocarcinoma or esophagogastric junction adenocarcinoma was stage III; Patients with postoperative pathological stage of intestinal cancer T1-3N2M0 or T4N+M0 8.No metastasis or recurrence was determined based on images taken after surgery and within the first 28 days of randomization 9. Subjects are required to provide sufficient FFPE tumor tissue specimens or sections for relevant testing 10.The functions of important organs must meet the following requirements:\n\n1. Hematological system（No blood component or cell growth factor was used to support treatment within 7 days prior to the start of study therapy）:\n\n   Neutrophil count≥1.5×10\\^9\u002FL; Platelet count≥100×10\\^9\u002FL; Hemoglobin≥90g\u002FL;\n2. Liver function： Serum albumin≥28g\u002FL; Total bilirubin (TBI)≤1.5×ULN; Alanine aminotransferase (ALT)≤3×ULN Aspartate aminotransferase (AST)≤2.5×ULN\n3. Renal function:\n\n   Serum creatinine ≤1.5×ULN Calculated creatinine clearance≥50 mL\u002Fmin (using the Cockcroft-Gault formula); Female: CrCl = (140- age in years) × weight in kg × 0.85 72 × serum creatinine in mg\u002F dL\n\n   Male: CrCl = (140- age in years) × weight in kg × 1.00 72 × serum creatinine in mg\u002F dL\n4. Coagulation function:\n\n   Subjects not receiving anticoagulation therapy: INR or APTT ≤ 1.5×ULN;\n5. Cardiac function: Left ventricular ejection fraction (LVEF)≥ 50 10. Fertile female subjects must undergo a urine or serum pregnancy test within 3 days prior to the first dosing (if the urine pregnancy test result is not confirmed negative, a serum pregnancy test is required, depending on the serum pregnancy result), and the result is negative If a fertile female subject has sex with an unsterilized male partner, the subject must use a highly effective contraceptive method since screening and must consent to continued use of the contraceptive method for 120 days after the last administration of the study drug; Whether to stop contraception after this time point should be discussed with the investigator 11.If an unsterilized male subject has sex with a fertile female partner, the subject must use an effective contraceptive method from the beginning of screening until the 120th day after the last dose; Whether to stop contraception after this time point should be discussed with the investigator.\n\n12.Subjects were willing and able to comply with the schedule for visiting treatment protocol laboratory tests and other study requirements.\n\nExclusion Criteria:\n\n1. Subjects with other malignancies in the 5 years prior to enrolment do not exclude subjects with other malignancies that have been cured by local treatment, such as basal or skin squamous cell carcinoma superficial bladder cancer cervix or breast carcinoma in situ\n2. Have received non-surgical treatment for gastric\u002Fesophagogastric junction\u002Fbowel cancer (e.g., radiotherapy, chemotherapy and hormone therapy)\n3. Liver peritoneum or distant metastasis\n4. Inability to take medications orally\n5. Unrelieved postoperative complications during screening (such as postoperative infection, suture rupture, gastrointestinal bleeding, pancreatic leakage, etc.)\n6. There are chemotherapy drugs contraindicated in this study and any group of adjuvant therapy regiments specified in the regimen cannot be accepted\n7. People with active autoimmune diseases that have required systemic treatment within the past two years (such as treatment with disease-modifying drugs, corticosteroids, immunosuppressants) and replacement therapy (such as insulin thyroxine or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) are not considered a systemic treatment\n8. There is a pleural, pericardial or abdominal effusion that is clinically symptomatic, requires diuretic treatment and\u002For requires repeated drainage.\n9. There are active or recurrent inflammatory gastrointestinal diseases (such as Crohn's disease ulcerative colitis hemorrhagic enteritis chronic diarrhea, etc.)\n10. A history of myocarditis and cardiomyopathy with malignant arrhythmias.Unstable angina pectoris, myocardial infarction, congestive heart failure (grade 2 or higher according to the New York Heart Association Functional Scale), or vascular disease (such as an aortic aneurysm at risk of rupture) requiring hospitalization in the 12 months prior to initial administration,Or other heart damage that may affect the safety evaluation of the investigational drug (e.g., poorly controlled arrhythmias, myocardial ischemia)\n11. Medically difficult to control hypertension (systolic blood pressure ≥150mmHg and\u002For diastolic blood pressure ≥100mmHg) (based on an average of ≥2 measurements).\n12. Uncontrolled diabetes.\n13. Peripheral neuropathy ≥ grade 2.\n14. Severe infection within 4 weeks prior to initial dosing, including but not limited to comorbidized sepsis or severe pneumonia requiring hospitalization; Active infections that have received systemic anti-infective therapy within 2 weeks prior to initial dosing (excluding antiviral therapy for hepatitis B or C)\n15. Known active tuberculosis (TB), suspected active TB subjects need to undergo clinical examination to rule out; Known active syphilis infection\n16. Subjects with current active hepatitis B (HBsAg positive with more than 2000 copies \u002Fml(500 IU\u002Fml) of HBV-DNA or higher than the lower limit of detection, whichever is higher), for subjects with hepatitis B, are required to receive anti-HBV therapy during the study treatment; Active hepatitis C subjects (HCV antibody positive with HCV-RNA levels above the lower limit of detection)\n17. History of immune deficiency; HIV antibody test positive; Systemic corticosteroid hormones or other immunosuppressants are currently being used on a long-term basis\n18. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation\n19. Prior treatment with PD-1 receptor or its ligand PD-L1 or cytotoxic T lymphocyte-associated protein 4(CTLA-4) receptor\n20. Known allergy to any component of any investigational drug; There is a known history of severe hypersensitivity to other monoclonal antibodies\n21. Inactivated vaccines are allowed if a live or attenuated vaccine has been administered in the 30 days prior to the first dose, or if a live or attenuated vaccine is planned to be administered during the study\n22. Known history of mental illness substance abuse alcohol or drugs\n23. Pregnant or lactating women\n24. The presence of any past or current abnormality in laboratory tests for treatment of disease that may confuse the study results, affect the subject's full participation in the study, or participation in the study may not be in the subject's best interest\n25. Local or systemic disease caused by non-malignant tumors; Or disease or symptoms secondary to the tumor and can lead to higher medical risk and\u002For uncertainty in the evaluation of survival\n26. Any condition that the investigator believes may cause subjects to receive the study drug treatment to be at risk of interfering with the evaluation of the study drug, or affecting the interpretation of the study results",{"count":105,"type":21},[107],"Objective of this study to evaluate 1-year disease-free survival in patients with dMMR\u002FMSI-H or POLE\u002FPOLD1 gene mutations with gastric or esophagus-gastric junctional adenocarcinoma or colorectal adenocarcinoma after chemotherapy-sequential tiralizumab adjuvant radical resection (based on RECIST v1.1 criteria).",[465,466],"Gastric","Colorectal Adenocarcinoma",[468,469,470,471,472,473],"radical resection","adjuvant therapy","gastric","colorectal adenocarcinoma","esophagogastric junction adenocarcinoma","dMMR\u002FMSI-H or POLE\u002FPOLD1 mutations","2023-11-01",{"date":476,"type":40},"2023-11-07",{"date":474,"type":21},{"date":479,"type":21},"2026-12-31",{"name":45,"class":46},{"id":482,"slug":4,"hasResults":10,"nctId":483,"briefTitle":484,"officialTitle":485,"acronym":4,"eligibilityCriteria":486,"healthyVolunteers":214,"sex":16,"minAge":76,"maxAge":18,"enrollmentInfo":487,"targetDuration":4,"studyType":22,"phases":488,"briefSummary":489,"conditions":490,"keywords":492,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":474,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":499,"leadSponsor":501,"locationsCount":4},"100525200","NCT06118645","Cadonilimab+ Paclitaxel (Albumin-bound) Treat Advanced Gastric Adenocarcinoma With PD-(L)1 Inhibitors Resistance","An Open, Multicenter, Phase II Study of Cadonilimab Combined With Paclitaxel (Albumin-bound) in the Treatment of Advanced Gastric Adenocarcinoma or Esophagogastric Junction Adenocarcinoma With PD-(L)1 Inhibitors Resistance","Inclusion Criteria:\n\n1. Be able to understand and voluntarily sign a written informed consent, which must be signed prior to performing the specified study procedure required for the study.\n2. Age and gender: ≥18 years old and≤75 years old, both men and women.\n3. The Eastern United States Cancer Collaborative (ECOG) physical Fitness score was 0-1.\n4. Histologically or cytologically confirmed unresectable or metastatic gastric adenocarcinoma or esophagogastric junction adenocarcinoma (EGJ defined as the center of the tumor within 5 cm of the anatomic location of the cardia, as described in the Siewert classification system).\n5. Patients who have progressed or become intolerant after prior treatment with a regimen containing PD-1\u002FPD-L1 monoclonal antibody had a tumor shrinkage response assessed as CR, PR, or reduced SD(\\\u003C0% reduction in total target lesion diameter from baseline according to RECIST v 1.1) and persisted for 4 months or more after treatment with PD-1\u002FPD-L1 monoclonal antibody If the disease progresses during neoadjuvant\u002Fadjuvant chemotherapy or radical chemoradiotherapy or within 6 months after the end of the last treatment, it is considered to have received first-line treatment\n6. Expected survival ≥12 weeks.\n7. According to RECIST v1.1, subjects must have at least one measurable lesion. For subjects who have previously received radiotherapy, a radiation-treated lesion may be considered a target if there is objective evidence of significant progression after radiotherapy if there is no other alternative target lesion.\n8. Subjects are required to provide the most recent archived (at least 2 years old) and\u002For freshly obtained tumor tissue samples and at least 3 unstained FFPE pathological slides.\n9. The functions of important organs must meet the following requirements:\n\n(1) Hematological system: Neutrophil count≥1.5×10\\^9\u002FL; Platelet count≥100×10\\^9\u002FL; Hemoglobin≥90g\u002FL; (2) Liver function： Serum albumin≥28g\u002FL; Total bilirubin (TBI)≤1.5×ULN; Alanine aminotransferase (ALT)≤3×ULN (or≤5×ULN if liver metastates are present); Aspartate aminotransferase (AST)≤2.5×ULN (or≤5×ULN if liver metastates are present); (3) Renal function: Calculated creatinine clearance≥50 mL\u002Fmin (using the Cockcroft-Gault formula); Female: CrCl = (140- age in years) × weight in kg × 0.85 72 × serum creatinine in mg\u002F dL\n\nMale: CrCl = (140- age in years) × weight in kg × 1.00 72 × serum creatinine in mg\u002F dL\n\nUrinary protein 2+ or 24 hours (h) urinary protein quantification\\\u003C1.0g. (4) Coagulation function: Subjects not receiving anticoagulation therapy: INR or APTT ≤ 1.5×ULN; (5) Cardiac function: Left ventricular ejection fraction (LVEF)≥ 50 10. Fertile female subjects must undergo a urine or serum pregnancy test within 3 days prior to the first dosing (if the urine pregnancy test result is not confirmed negative, serum pregnancy test is required, based on the blood pregnancy result), and the result is negative if the fertile female subject is not neutered The subject must be on a highly effective contraceptive method since screening and must consent to continued use of the contraceptive method for 120 days after the last dose of the study drug; Whether to stop contraception after this time point should be discussed with the investigator.\n\n11.If an unsterilized male subject has sex with a fertile female partner, the subject must use an effective contraceptive method from the beginning of screening until the 120th day after the last dose; Whether to stop contraception after this time point should be discussed with the investigator.\n\n12.Subjects were willing and able to comply with the schedule for visiting treatment protocol laboratory tests and other study requirements.\n\nExclusion Criteria:\n\nPatients with any of the following criteria were excluded from the study\n\n1. Other pathological types confirmed by histopathological or cytological examination, such as squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma and Mixed pathological types will be judged according to the main components, adenocarcinoma components confirmed by the pathologist greater than 70% can be included in the group\n2. Participants had other malignancies within 3 years prior to enrollment. Subjects with other malignancies that have been cured by local treatment, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical cancer, or carcinoma in situ of the breast, are not excluded.\n3. The last systemic anti-tumor therapy, including chemotherapy and radiotherapy, immunotherapy, targeted therapy (small molecule targeted therapy is within 2 weeks before the first drug administration), and biologic therapy, was received within 3 weeks before the first drug administration; Palliative local treatment for non-target diseases and foci was performed within 2 weeks before the first administration; Received systemic non-specific immunomodulatory therapy (e.g., interleukin, interferon, thymosin, etc.) within 2 weeks prior to initial administration; Received Chinese herbal medicine or proprietary Chinese medicine with anti-tumor indications within 2 weeks prior to the first administration。\n4. Previously received immunotherapy other than PD-1\u002FPD-L1 inhibitors, including immune checkpoint inhibitors (such as anti-CTLA-4 antibodies, anti-CD47 antibodies, anti-SIRP-α antibodies, anti-LAG-3 antibodies, etc.), immune checkpoint agonists, and immune cell therapy Any treatment targeting the immune mechanism of tumor action.\n5. Taxoids have been used in anti-tumor therapy in the past (including chemotherapy drugs such as paclitaxel and docetaxel)..\n6. HER-2 overexpression (immunohistochemistry 2+ and FISH+, and immunohistochemistry 3+) did not use anti-HER-2 therapy (including trastuzumab, etc.) in previous anti-tumor therapy.\n7. Any of the following has occurred during previous treatment with PD-1\u002FPD-L1 inhibitors:\n\n(1)There has been a history of grade 3 or higher irAE(excluding endosecretory system-related irAE) from PD-1\u002FPD-L1 inhibitor therapy that resulted in permanent discontinuance of therapy, grade 2 immune-related cardiotoxicity, or any grade of neurological or ocular irAE; (2)Prior to screening in this study, subjects who were treated with prior PD-1\u002FPD-L1 inhibitors and did not have complete remission of all adverse events or did not have remission to grade 1 were admitted to the study if their condition was stable and asymptomatic with appropriate alternative therapy; (3)Previous adverse events requiring immunosuppressant therapy other than glucocorticoids or recurrent adverse events during prior immunotherapy requiring systemic glucocorticoid therapy.\n\n8\\. People with active autoimmune diseases that have required systemic treatment within the past two years (such as treatment with disease-modifying drugs, corticosteroids, immunosuppressive agents) and replacement therapy (such as thyroxine, islet, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) are not considered a systemic treatment.\n\n9\\. Subjects with known active or untreated brain metastases, meningeal metastases, spinal cord compression, or pIA disease are admitted if they meet the following requirements and have measurable lesions outside the central nervous system: Asymptomatic after treatment, radiologically stable for at least 4 weeks prior to the start of study therapy (e.g. no new or enlarged brain metastases), and systemic glucocorticoid and anticonvulsant therapy have been discontinued for at least 2 weeks.\n\n10\\. The presence of pleural effusion, pericardial effusion or peritoneal effusion with clinical symptoms requiring diuretic treatment and\u002For repeated drainage.\n\n11\\. Clinically significant gastrointestinal obstruction, gastrointestinal perforation, intraperitoneal abscess, and fistula formation occurred within 6 months before first administration.\n\n12\\. The presence of active or recurrent inflammatory gastrointestinal diseases (e.g. Crohn's disease ulcerative colitis radiation enteritis hemorrhagic enteritis chronic diarrhea, etc.) 13. History of myocarditis, cardiomyopathy, and malignant arrhythmias, Unstable angina pectoris requiring hospitalization, myocardial infarction, congestive heart failure (grade 2 or higher as defined by the New York Heart Association Functional Scale), or vascular disease (such as risk of rupture) in the 12 months prior to initial administration Aneurysms), or other heart damage that may affect the safety evaluation of the investigational drug (e.g., poorly controlled arrhythmias, myocardial ischemia).\n\n14\\. Severe infection within 4 weeks prior to initial dosing, including but not limited to comorbiditic sepsis or severe pneumonia that requires hospitalization; Active infections that have received systemic anti-infective therapy within 2 weeks prior to initial dosing (excluding antiviral therapy for hepatitis B or C) 15. Subjects with known active tuberculosis (TB) and suspected active TB should be clinically screened for exclusion; Known active syphilis infection 16. Subjects with current active hepatitis B (HBsAg positive with more than 1000 copies \u002Fml(200 IU\u002Fml) of HBV-DNA or higher than the lower limit of detection, whichever is higher) are required to receive anti-HBV therapy during the study treatment for those with hepatitis B; Active hepatitis C subjects (HCV antibody positive with HCV-RNA levels above the lower limit of detection).\n\n17\\. Subjects with current active hepatitis B (HBsAg positive with more than 1000 copies \u002Fml(200 IU\u002Fml) of HBV-DNA or higher than the lower limit of detection, whichever is higher) are required to receive anti-HBV therapy during the study treatment for those with hepatitis B; Active hepatitis C subjects (HCV antibody positive with HCV-RNA levels above the lower limit of detection).\n\n18\\. The history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation is known 19.No remission of toxicity from prior antitumor therapy, defined as toxicity not returning to the level specified in the NCI CTCAE Version 5.0, level 0 or level 1, or in the inclusion\u002Fexclusion criteria, except for hair loss in subjects who develop irreversible toxicity and are not expected to be aggravated after administration of the investigational drug (e.g., hearing loss) After consultation, subjects may be included in the study of long-term toxicity caused by radiation therapy, and those who are judged by the investigator to be unable to recover may be included in the study.\n\n20.Known allergy to any component of any investigational drug; There is a known history of severe hypersensitivity to other monoclonal antibodies.\n\n21.If a live or attenuated vaccine has been administered within 30 days prior to the first dose, or if a live or attenuated vaccine is planned to be administered during the study period, inactivated vaccine use is permitted.\n\n22.Known history of mental illness substance abuse alcohol or drugs 23. Pregnant or lactating women 24.The presence of any past or current abnormality in laboratory tests for treatment of disease that may confuse the study results, affect the subject's full participation in the study, or that participation in the study may not be in the subject's best interest.\n\n25.Local or systemic diseases caused by non-malignant tumors; Or disease or symptoms secondary to the tumor that may lead to higher medical risk and\u002For uncertainty in the evaluation of survival, such as tumor leukemia-like reactions, manifestations of cachexia, etc 26.Any condition that the investigator believes may cause the subject to receive the study drug treatment to be at risk of interfering with the evaluation of the study drug, or affecting the interpretation of the study results。",{"count":242,"type":21},[107],"Cadonilimab combined with paclitaxel (albumin-bound) treat advanced gastric adenocarcinoma or esophagogastric junction adenocarcinoma with PD-(L)1 inhibitors resistance",[491],"Gastric Adenocarcinoma",[493,494,495,496,472],"cadonilimab","paclitaxel (albumin-bound)","gastric adenocarcinoma","PD-(L)1 inhibitors resistance",{"date":476,"type":40},{"date":474,"type":21},{"date":500,"type":21},"2026-08-01",{"name":45,"class":46},{"id":503,"slug":4,"hasResults":10,"nctId":504,"briefTitle":505,"officialTitle":505,"acronym":4,"eligibilityCriteria":506,"healthyVolunteers":10,"sex":16,"minAge":76,"maxAge":124,"enrollmentInfo":507,"targetDuration":4,"studyType":22,"phases":509,"briefSummary":510,"conditions":511,"keywords":513,"overallStatus":87,"whyStopped":4,"lastUpdateSubmitDate":516,"lastUpdatePostDateStruct":517,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":96},"100484866","NCT05593627","Effect of Lithium Carbonate on Postoperative Sleep and Cognitive Function in Patients Undergoing Heart Valve Surgery With Cardiopulmonary Bypass","Inclusion Criteria:\n\n* Ethnic Chinese;\n* Age, 18 to 65 years old;\n* Patients undergoing heart valve surgery with cardiopulmonary bypass\n\nExclusion Criteria:\n\n* Preoperative Pittsburgh Sleep Quality Index global scores higher than 6\n* Cognitive difficulties\n* Partial or complete gastrectomy\n* Previous esophageal surgery\n* Previous treated by radiotherapy or surgery\n* Inability to conform to the study's requirements\n* Body mass index exceeding 30 kg\u002Fm2\n* Deprivation of a right to decide by an administrative or juridical entity\n* Ongoing participation or participation in another study \\\u003C1 month ago\n* Recent (\\\u003C 3 months prior) use of antibiotics, probiotics, prebiotics, symbiotics, hormonal medication, laxatives, proton pump inhibitors, insulin sensitizers or traditional Chinese medicine",{"count":508,"type":21},62,[128],"It has been proved that lithium carbonate can prolong slow wave sleep with few or no side-effects. The aim of the present study is to evaluate postoperative sleep quality of patients undergoing heart valve surgery with cardiopulmonary bypass taken 250mg lithium carbonate after surgery.",[512],"Heart Valve Surgery",[514,515],"lithium carbonate","polysomnography","2023-07-14",{"date":518,"type":40},"2023-07-18",{"date":520,"type":40},"2023-07-01",{"date":522,"type":21},"2026-07-30",{"name":45,"class":46},""]